Medical term:
cape
CAPE
Cardiology(1) Carotid Assessment Program for the Elderly.
(2) Circadian Anti-ischemia Program in Europe. A trial which evaluated the effect of an anti-ischemic calcium-channel blocker, amlodipine, on morbidity and mortality in patients with symptomatic chronic stable angina (CSA).
Conclusion
Amlodipine reduces syptomatic ischemia and ECG/EKG-evident ischemia in patients with CSA.
CAPE
Cardiology A clinical trial–Circadian Anti-Ischemia Program in Europe that evaluated the effect of an anti-ischemic, amlodipine, on M&M in Pts with CAD. See Amlodipine, Coronary artery disease, Silent ischemia.CAPE
Abbrev. for Clifton assessment procedure for the elderly. This is a series of tests to assess the mental and behavioural capacity of old people.Patient discussion about CAPE
Q. skins does excrete oil and keratin what exactly is the whitish cape up that you can squeeze out from underskin
You may read more here:
http://en.wikipedia.org/wiki/Sebum#Sebum
capecitabine
[kap″ĕ-si´tah-bēn]capecitabine
Pharmacologic class: Fluoropyrimidine, antimetabolite (pyrimidine analog)
Therapeutic class: Antineoplastic
Pregnancy risk category D
FDA Box Warning
• In patients receiving concomitant oral coumarin-derivative anticoagulants (such as warfarin and phenprocoumon), monitor International Normalized Ratio (INR) or prothrombin time (PT) frequently to allow appropriate anticoagulant dosage adjustment. Altered coagulation parameters, bleeding, and death have occurred in patients taking this drug combination. Postmarketing reports show significant INR and PT increases in patients stabilized on anticoagulants when capecitabine therapy began. Age older than 60 and cancer diagnosis independently increase coagulopathy risk.
Action
Enzymatically converts to 5-fluorouracil, which injures cells by interfering with DNA synthesis, cell division, RNA processing, and protein synthesis
Availability
Tablets: 150 mg, 500 mg
Indications and dosages
➣ Metastatic breast cancer resistant to both paclitaxel and a chemotherapy regimen that includes anthracycline; metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred
Adults: Initially, 2,500 mg/m2/day P.O. in two divided doses for 2 weeks, followed by a 1-week rest period; administered in 3-week cycles
Dosage adjustment
• Renal impairment
• Hepatic impairment
• Elderly patients
Contraindications
• Hypersensitivity to drug
• Severe renal impairment
• Pregnancy or breastfeeding
Precautions
Use cautiously in:
• mild to moderate renal impairment, hepatic impairment, severe diarrhea, coronary artery disease, intestinal disease, infection, coagulopathy
• children younger than age 18.
Administration
• Give with water within 30 minutes after a meal.
• If dosage must be lowered because of toxicity, don't increase dosage later.
Adverse reactions
CNS: dizziness, fatigue, headache, insomnia, paresthesia
CV: edema
EENT: eye irritation
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, stomatitis, intestinal obstruction
Hematologic: anemia, lymphopenia, neutropenia, thrombocytopenia
Metabolic: dehydration
Musculoskeletal: myalgia, limb pain
Skin: dermatitis, alopecia, nail disorder, hand and foot syndrome (palmarplantar erythrodysesthesia)
Other: fever
Interactions
Drug-drug. Antacids: increased capecitabine blood level
Leucovorin: increased cytotoxicity
Live-virus vaccines: impaired ability to mount an immune response to vaccine
Phenytoin: increased phenytoin blood level
Warfarin: increased risk of bleeding
Drug-diagnostic tests. Bilirubin: increased level
Hemoglobin, neutrophils, platelets, white blood cells: decreased levels
Patient monitoring
• Monitor patient for signs and symptoms of toxicity. Be prepared to reduce dosage or withhold drug when indicated.
• Stay alert for signs and symptoms of infection.
• Carefully assess fluid and electrolyte status if patient has severe diarrhea.
• Monitor weight, CBC, International Normalized Ratio, prothrombin time, and kidney and liver function test results.
• Evaluate closely for adverse reactions in patients older than age 80.
Patient teaching
• Advise patient to take drug with water within 30 minutes after a meal.
➣ Instruct patient to immediately report nausea, vomiting, diarrhea, mouth ulcers, swollen joints, temperature above 100.5 °F (38 °C), and other signs or symptoms of infection.
• Tell patient to expect dosage adjustments during therapy.
• Urge patient to use reliable birth control method because drug may harm fetus if she becomes pregnant.
• Caution patient not to breastfeed during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
capecitabine
(kap-e-sit'ă-bēn),capecitabine
(kăp′ə-sī′tə-bēn′)capecitabine
An anticancer drug used especially in treatment of cancers of the rectum or colon that have been found to have spread. The drug is noticeably less liable to produce undesirable side effects than other forms of anticancer chemotherapy. It is also used in the treatment of breast cancer with some success. A brand name is Xeloda.Latest Searches:
viverrini - Vivelle - vivax - vivarium - Vivarin - vivaria - Vivaglobin - VivaGel - Vivactil - ViVa - Vitus - vitulorum - vitrum - Vitros - Vitropin - vitronectin - vitro - vitriol - vitrinus - vitrina -
- Service manuals - MBI Corp